Capacity for Compensatory Cyclin D2 Response Confers Trametinib Resistance in Canine Mucosal Melanoma
Open Access
Abstract
Background/objective: Mucosal melanoma (MM) is a poorly responsive, rare and aggressive subtype with few cases having targetable recurrent driver mutations, although Ras/MAPK and PI3K/AKT/mTOR signaling pathway activations are common. Eventual tumor evasion of targeted therapy continues to limit treatment success. Adequate models are necessary to address therapeutic resistance. The relatively greater incidence of naturally occurring MM in dogs, as well as its comparable clinical and pathological characteristics to human MM, represents an opportunity for study as a human MM patient surrogate. Resistance-promoting crosstalk between Ras/MAPK and PI3K/AKT/mTOR signaling under trametinib inhibition of MEK was studied in canine MM. Emphasis was placed on the suppressive effect of trametinib on cell cycle entry and its potential role in drug resistance. Methods: D-type cyclins were investigated following trametinib treatment of five MM cell lines exhibiting differential drug sensitivities. Signaling pathway activation, proliferation, survival, cell death, and cell cycle were analyzed in the context of D-type cyclin expression. Cyclin D2 expression was manipulated using siRNA knockdown or inducible recombinant overexpression. Results: Trametinib diminished cyclin D1 in all cell lines. While relatively trametinib-resistant MM cells exhibited capacity to upregulate cyclin D2, which promoted proliferation, sensitive MM cells lacked similar cyclin D2 compensation. Inhibition of the compensatory cyclin D2 in resistant cells conferred sensitivity. Induced cyclin D2 overexpression in otherwise trametinib-sensitive MM cells promoted survival. Upregulated PI3K/AKT/mTOR signaling under trametinib treatment was suppressed by mTORC1/2 inhibition, which similarly diminished cyclin D2 response. Conclusions: The compensatory switch from preferential reliance on cyclin D1 to D2 plays a role in MM resistance to MEK inhibition.Keywords
All Related Versions
Funding Information
- Intramural Research Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
This publication has 72 references indexed in Scilit:
- Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional ProfilesJournal of Investigative Dermatology, 2022
- Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta‐analysisCancer Medicine, 2019
- Mechanisms of Drug Resistance in Melanoma2017
- Cyclin D1 Amplification in Multiple Myeloma Is Associated With Multidrug Resistance ExpressionClinical Lymphoma Myeloma and Leukemia, 2014
- The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivoThe Veterinary Journal, 2013
- Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutationsHuman Pathology, 2013
- Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocationsBlood Cancer Journal, 2012
- Canine malignant melanoma alpha-3 integrin binding peptidesVeterinary Immunology and Immunopathology, 2011
- KIT as a Therapeutic Target in Metastatic MelanomaJAMA, 2011
- Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignanciesLeukemia Research, 2001